Table 5.
Main studies reporting anakinra administration in pediatric CNO.
| Type of study | Patients (n) | Dose | CR* | PR** | Adverse events | Median follow up (months) | |
|---|---|---|---|---|---|---|---|
| Pardeo et al.89 | Retrospective | 9 | 2–2.3 mg/kg/day | 0% | 89% (8/9) |
None | 20.4 (range 9.6–33.6) |
| Eleftheriou et al.88 | Case report | 1 | 2 mg/kg/day | / | 100% | None | 12 |
*
CR defined as no symptoms and radiological resolution of all bone lesions and no appearance of new bone lesions.
**
PR defined as symptoms improvement and/or decrease of radiological bone lesions.
CNO, chronic non-bacterial osteomyelitis; CR, complete response; NA, not available; PR, partial response.